GlassScriptPhysician profile
John R Treer
NPI 1972521110
$9,835.22
in general payments reported to CMS, 2019-2025
44 companies · $854 in 2025
The $854 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,528 · 2020: $1,297 · 2021: $1,583 · 2022: $1,734 · 2023: $1,589 · 2024: $1,251 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,693.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,250.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $815.94 | 2019-2024 | Spravato, Xarelto |
| Glaxosmithkline, LLC. | $814.28 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $701.82 | 2019-2025 | |
| Lilly USA, LLC | $657.30 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $632.94 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $554.83 | 2019-2025 | Belsomra, Steglatro, Steglujan |
| Abbvie INC. | $500.92 | 2019-2025 | Ubrelvy |
| Amgen INC. | $498.05 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $473.96 | 2019-2025 | Jardiance, Ofev |
| Abbott Laboratories | $454.41 | 2019-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $305.66 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $303.82 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $188.03 | 2019-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $157.31 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Treer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.